Consistent with the in vitro results, in vivo tumorigenesis studies demonstrated that Gal-1 knockdown significantly slowed tumor growth, particularly when combined with enzalutamide treatment (shGal-1 combined with enzalutamide vs. shGal-1 alone, p < 0.001; the mean luminescence intensity was 2.3 × 104 for the group treated with shGal-1 combined with enzalutamide compared with 11.5 × 104 for the shGal-1 transfected group) (Figure 2D,E). This evidence concerns the gene LGALS1 and neoplasm.